Welcome to Visited Lingnan Modern Clinics In Surgery, Today is

Lingnan Modern Clinics In Surgery ›› 2021, Vol. 21 ›› Issue (04): 482-488.DOI: 10.3969/j.issn.1009-976X.2021.04.023

• Review • Previous Articles     Next Articles

Targeted therapy and immuno-therapy of non-small cell lung cancer harboring rare mutation in EGFR

FENG Hui-yi, WU Ming-wei   

  1. Department of Oncology, Shenzhen Hospital of Southern Medical University, shenzhen, Guangdong 518110, China
  • Contact: WU Ming-wei, mingweiwu@hotmail.com

非小细胞肺癌EGFR罕见突变及其靶向与免疫治疗策略

冯惠仪, 吴明玮*   

  1. 南方医科大学深圳医院肿瘤科,广东深圳 518110
  • 通讯作者: *吴明玮,Email: mingweiwu@hotmail.com
  • 基金资助:
    深圳市宝安区医疗卫生基础项目研究(2017JD034)

Abstract: Two types of activation mutations were found in epidermal growth factor receptor (EGFR): classical mutation and rare mutation, with diverse response to EGFR-TKI treatment or immuno-therapy. It was systemically reviewed the pre-clinical and clinical studies on rare mutations of EGFR of non-small cell lung cancer in this paper.

Key words: non-small cell lung cancer, EGFR mutation, rare mutation, targeted therapy, immunetherapy

摘要: 表皮生长因子受体(EGFR)基因的激活突变包括经典突变和罕见突变。罕见突变病人数量少,不同突变类型对不同的EGFR酪氨酸激酶抑制剂的敏感性差异较大。本文将对各种罕见突变进行系统回顾,总结针对罕见突变的临床前研究和临床研究,为临床治疗决策提供依据。

关键词: 非小细胞肺癌, EGFR突变, 罕见突变, 靶向治疗, 免疫治疗

CLC Number: